TY - CHAP M1 - Book, Section TI - Key Clinical Trials and Publications in Pulmonology A1 - Huppert, Laura A. A1 - Dyster, Timothy G. PY - 2021 T2 - Huppert’s Notes: Pathophysiology and Clinical Pearls for Internal Medicine AB - Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. New Engl J Med 1991; 325:388–92.- Randomized, blinded trial comparing terbutaline and budesonide, which provided early evidence useful for establishing inhaled corticosteroids as a first-line treatment in asthma management.The Salmeterol Multicenter Asthma Research Trial (SMART).Chest 2006;129(1):15–26.- Randomized, double-blinded, placebo-controlled trial of salmeterol BID for asthma in patients >12 yr old. Demonstrated a small but statistically significant increase in respiratory- and asthma-related deaths for the population receiving salmeterol, particularly for African Americans who were enrolled in the trial.As-needed budesonide-formoterol versus maintenance budesonide in mild asthma.N Engl J Med 2018;378(20):1877–1887.- Randomized, double-blinded, placebo-controlled trial that demonstrated budesonide–formoterol PRN was noninferior to budesonide BID with respect to the rate of severe asthma exacerbations and resulted in approximately one-quarter of the inhaled glucocorticoid exposure. However, symptom control was inferior in the budesonide–formoterol PRN group. SN - PB - McGraw Hill CY - New York, NY Y2 - 2024/03/29 UR - accessmedicine.mhmedical.com/content.aspx?aid=1189912717 ER -